Companies › Creative Medical Technology Holdings
1 active drug program in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CELZ-201-DDT Perinatal tissue-derived cells for beta cell regeneration/preservation in Type 1 Diabetes | – | Phase 1 | Chronic Low-back Pain; Type 1 Diabetes | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06053242 | CELZ-201-DDT | Phase 1 | Chronic Low-back Pain | Other | Jan 2027 |
| NCT05626712 | CELZ-201-DDT | Phase 1 | Type 1 Diabetes | Metabolic and endocrine | Jan 2027 |
Cash of $7m on 2026-09-30; operating cash outflow about $6m a year; runway about 14 months at that burn, to Nov 2027
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.